Shares

11 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2022

Feb 10, 2023

SELL
$0.74 - $1.83 $10,792 - $26,690
-14,585 Reduced 12.15%
105,484 $93,000
Q3 2022

Nov 14, 2022

SELL
$1.51 - $2.88 $4,824 - $9,201
-3,195 Reduced 2.59%
120,069 $190,000
Q2 2022

Aug 10, 2022

SELL
$1.24 - $2.33 $8,851 - $16,631
-7,138 Reduced 5.47%
123,264 $250,000
Q1 2022

May 04, 2022

SELL
$2.0 - $4.9 $108,848 - $266,677
-54,424 Reduced 29.45%
130,402 $3.98 Million
Q3 2021

Nov 05, 2021

SELL
$7.41 - $10.99 $1,118 - $1,659
-151 Reduced 0.08%
184,826 $1.4 Million
Q2 2021

Aug 02, 2021

SELL
$6.35 - $10.0 $299,866 - $472,230
-47,223 Reduced 20.34%
184,977 $1.8 Million
Q1 2021

May 13, 2021

BUY
$7.03 - $16.51 $182,442 - $428,467
25,952 Added 12.58%
232,200 $1.92 Million
Q4 2020

Feb 10, 2021

BUY
$5.76 - $11.95 $28,621 - $59,379
4,969 Added 2.47%
206,248 $1.41 Million
Q3 2020

Nov 12, 2020

BUY
$6.17 - $18.82 $534,655 - $1.63 Million
86,654 Added 75.6%
201,279 $2.21 Million
Q2 2020

Aug 14, 2020

BUY
$1.73 - $6.76 $179,747 - $702,364
103,900 Added 968.76%
114,625 $721,000
Q1 2020

May 18, 2020

BUY
$1.57 - $4.76 $16,838 - $51,051
10,725 New
10,725 $21,000

Others Institutions Holding SRNE

About Sorrento Therapeutics, Inc.


  • Ticker SRNE
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 449,952,000
  • Market Cap $148M
  • Description
  • Sorrento Therapeutics, Inc., a clinical stage and commercial biopharmaceutical company, develops therapies for cancer, autoimmune, inflammatory, viral, and neurodegenerative diseases. It operates through two segments, Sorrento Therapeutics and Scilex. The company provides cancer therapeutic by leveraging its proprietary G-MAB antibody library an...
More about SRNE
Track This Portfolio

Track Advisor Group Holdings, Inc. Portfolio

Follow Advisor Group Holdings, Inc. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Advisor Group Holdings, Inc., based on Form 13F filings with the SEC.

News

Stay updated on Advisor Group Holdings, Inc. with notifications on news.